



## **Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018**

January 30, 2018

### **Conference Call and Webcast to Follow**

WASHINGTON, Jan. 30, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: Vnda) today announced it will release results for the fourth quarter and full year 2017 on Wednesday, February 14, 2018, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, February 14, 2018, during which management will discuss the fourth quarter and full year 2017 financial results and other corporate activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) or 1-847-585-4405 (international) and use passcode 46291578.

The conference call will be broadcast simultaneously and archived on Vanda's website, [www.vandapharma.com](http://www.vandapharma.com). Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, February 14, 2018, beginning at 7:00 PM ET and will be accessible until Wednesday, February 21, 2018, at 11:59 PM ET. The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The passcode number is 46291578.

### **ABOUT VANDA PHARMACEUTICALS INC.:**

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit [www.vandapharma.com](http://www.vandapharma.com).

### **Investor Contact:**

Jim Kelly  
Executive Vice President & Chief Financial Officer  
Vanda Pharmaceuticals Inc.  
(202) 734-3428  
[jim.kelly@vandapharma.com](mailto:jim.kelly@vandapharma.com)

 View original content: <http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-february-14-2018-300590562.html>

SOURCE Vanda Pharmaceuticals Inc.